To investigate the effects of agonistic CD40 antibodies (αCD40) on the tumor microenvironment, we intravenously administered αCD40 or the corresponding rIgG2a isotype control to C57BL/6 mice with syngeneic gliomas. This evidence concerns the gene CD40 and glioma.